Raymond James Financial Services Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-35,079	Closed	-$6.44M	–	3458
2021 Q2	$6.44M	Buy	35,079 +3,820	+12%	+$656K	0.01%	860
2021 Q1	$4.78M	Sell	31,259 -8,861	-22%	-$1.37M	0.01%	927
2020 Q4	$6.27M	Sell	40,120 -10,372	-21%	-$1.33M	0.02%	741
2020 Q3	$5.78M	Buy	50,492 +18,439	+58%	+$1.99M	0.02%	698
2020 Q2	$3.6M	Sell	32,053 -2,466	-7%	-$262K	0.01%	840
2020 Q1	$3.1M	Buy	34,519 +10,320	+43%	+$1.01M	0.01%	697
2019 Q4	$2.62M	Buy	24,199 +1,568	+7%	+$168K	0.01%	1040
2019 Q3	$2.22M	Buy	22,631 +2,297	+11%	+$259K	0.01%	1049
2019 Q2	$2.66M	Buy	20,334 +279	+1%	+$36K	0.01%	947
2019 Q1	$2.71M	Sell	20,055 -2,243	-10%	-$279K	0.01%	921
2018 Q4	$2.17M	Buy	22,298 +548	+3%	+$64.8K	0.01%	860
2018 Q3	$3.02M	Sell	21,750 -5,726	-21%	-$718K	0.01%	859
2018 Q2	$3.41M	Buy	27,476 +1,464	+6%	+$171K	0.02%	762
2018 Q1	$2.9M	Sell	26,012 -1,423	-5%	-$170K	0.02%	779
2017 Q4	$3.28M	Sell	27,435 -3,109	-10%	-$379K	0.02%	706
2017 Q3	$4.29M	Sell	30,544 -4,238	-12%	-$576K	0.03%	582
2017 Q2	$4.23M	Buy	34,782 +2,871	+9%	+$334K	0.03%	566
2017 Q1	$3.87M	Sell	31,911 -20,522	-39%	-$2.65M	0.03%	573
2016 Q4	$6.42M	Sell	52,433 -99,772	-66%	-$12.2M	0.05%	374
2016 Q3	$18.7M	Sell	152,205 -478	-0.3%	-$61.5K	0.17%	146
2016 Q2	$17.8M	Buy	152,683 +4,775	+3%	+$677K	0.17%	146
2016 Q1	$20.6M	Buy	147,908 +30,907	+26%	+$4.54M	0.24%	97
2015 Q4	$22.3M	Buy	+117,001	New	+$20.4M	0.26%	90

Other funds holding ALXN